3SBio Inc. Announces Results of Annual General Meeting
SHENYANG, China, Nov. 23, 2010 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the results of its annual general meeting of s...
3SBio Announces Conversion of Isotechnika Debenture
SHENYANG, China, Nov. 19, 2010 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ("3SBio") (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products today announced that it has recently converted the remaining US$2....
3SBio Inc. Announces Unaudited Third Quarter Results
Third quarter revenues grew 24.9% year-over-year to RMB115.6 million (US$17.3 million); First nine months revenues grew 30.8% year-over-year to RMB317.4 million (US$47.4 million); Company reiterates FY2010 revenue guidance SHENYANG, China, Nov. 16, 2010 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ...
3SBio Inc. Schedules Third Quarter 2010 Unaudited Financial Results
SHENYANG, China, Oct. 18 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release unaudited financi...
3SBio Inc. to Hold 2010 Annual General Meeting on October 29, 2010
SHENYANG, China, Sept. 27 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that the annual general meeting of sh...
3SBio Announces Partial Conversion of Isotechnika Debenture
SHENYANG, China, Sept 14 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ("3SBio") (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products today announced that it has converted C$2.02 million (US$1.92 milli...
3SBio Announces Investor Conference Schedule
SHENYANG, China, Sept. 7 /PRNewswire-Asia/ -- 3SBio Inc. ("3SBio") (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products today announced its planned participation in the following investor conference...
3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China
SHENYANG, China, Aug. 24 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ("3SBio") (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products and Isotechnika Pharma Inc. ("Isotechnika") (TSX: ISA), a biopharmaceut...
3SBio Inc. Announces Unaudited Second Quarter Results
SHENYANG, China, Aug. 18 /PRNewswire-Asia-FirstCall/ -- -- Second quarter revenues grew 29.5% year-over-year to RMB105.5 million (US$15.6million); -- First half revenues grew 34.5% year-over-year to RMB201.9 million (US$29.8 million); -- Second quarter operating...
3SBio Inc. Schedules Second Quarter 2010 Unaudited Financial Results
SHENYANG, China, Aug. 5 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release unaudited ...
3SBio Inc. Announces Filing of Form 20-F With SEC
SHENYANG, China, June 28 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that on June 25, 2010, the C...
3SBio Inc. Announces Unaudited First Quarter 2010 Results
Net revenues grew 40.5% year-on-year to RMB96.4 million (US$14.1 million) Net income grew 67.8% year-on-year to RMB26.7 million (US$3.9 million) 2010 net revenues guidance increased to US$56-US$60 million SHENYANG, China, May 16 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX)...
3SBio Inc. To Report 2010 First Quarter Unaudited Financial Results on May 16, 2010
SHENYANG, China, May 11 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release unaudited financial re...
3SBio Announces Changes to its Board of Directors
SHENYANG, China, March 10 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced changes to its board of directors (the "Board"). Ms. Liping Xu,...
3SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results
Company exceeds guidance with 2009 revenue of RMB316.9 million (US$46.4 million) Full-year 2009 GAAP net income grew 111.0% year-over-year to RMB83.4 million (US$12.2 million) Provides 2010 net revenue guidance range of US$56-US$58 million SHENYANG, China, Feb. 12 /PRNewswire-Asia/ --...
3SBio Inc. Submits Application for NuPIAO Phase I Clinical Trial
SHENYANG, China, Feb. 12 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a Phase I clinical tri...
3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics
SHENYANG, China, Feb. 12 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pha...
3SBio Inc. to Report 2009 Fourth Quarter and Full Year Results on February 11, 2010
SHENYANG, China, Jan. 26 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release financial results for t...
3SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM)
SHENYANG, China, Jan. 8 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a registrational clinic...
3SBio Inc. Announces Unaudited Third Quarter 2009 Results
Third quarter revenue grew 35.8% year-over-year to RMB92.6 million (US$13.6 million); Operating income grew 37.8% year-over-year to RMB28.5 million (US$4.2 million); Company reiterates FY2009 revenue guidance SHENYANG, China, Nov. 13 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("...
